Evidence map›Paper›PMID 37081439›Full record

ArticleBMC women's health2023

Utility of vaginal vault cytology in the local recurrence of cervical cancer.

Kazuto Nakamura, Soichi Yamashita, Keiko Kigure, Toshio Nishimura, Ikuro Ito, Anri Azuma, Kohshiro Nakao, Ken Ando, Tatsuya Kanuma

Open access · goldAbstract read
In one paragraph

Article in BMC women's health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Kazuto NakamuraDepartment of Gynecology, Gunma Prefectural Cancer Center, Ota, Japan. nkazuto@gunma-cc.jp.
Soichi YamashitaDepartment of Gynecology, Gunma Prefectural Cancer Center, Ota, Japan.
Keiko KigureDepartment of Gynecology, Gunma Prefectural Cancer Center, Ota, Japan.
Toshio NishimuraDepartment of Gynecology, Gunma Prefectural Cancer Center, Ota, Japan.
Ikuro ItoDepartment of Obstetrics and Gynecology, Takasaki General Medical Center, Takasaki, Japan.
Anri AzumaDepartment of Obstetrics and Gynecology, Takasaki General Medical Center, Takasaki, Japan.
Kohshiro NakaoDepartment of Obstetrics and Gynecology, Gunma University, Maebashi, Japan.
Ken AndoDepartment of Radiation Oncology, Gunma University, Maebashi, Japan.
Tatsuya KanumaDepartment of Gynecology, Gunma Prefectural Cancer Center, Ota, Japan.
Hyogo Prefectural Cancer Center · JPGunma University · JPNational Hospital Organization Takasaki Medical Center · JPGunma Children's Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn Japan, 8000 women were newly diagnosed with cervical cancer in 2018. The healthcare insurance policy in Japan allows physicians to utilize vaginal volt cytology tests and serum biomarker measurement at every visit and imaging analysis at an adequate interval with screening for recurrence after initial treatment. However, the major surveillance guidelines published in the United States and European countries recommend focusing on pelvic examinations and symptom reviews to avoid unnecessary tests. This study aimed to reassess the benefits of standard surveillance methods adopted in this study by retrospective analysis.

methodsFrom January 2009 to December 2015, the medical records of patients with recurrence who were initially diagnosed with International Federation of Gynecology and Obstetrics stage I-III cervical cancer were collected for this study. Clinicopathological data were statistically analyzed to identify significant factors. In the first 2 years, the patients underwent regular surveillance, including pelvic examination, serum tumor marker tests, vaginal vault cytology every 1-3 months, and imaging analysis at 6- to 12-month intervals. In the following 2 years, the patients received a regular check with the same methods every 4 months and an annual imaging analysis. Afterward, the patients had regular screening every 6 to 12 months.

resultsIn the study period, 84 of the 981 patients experienced recurrence, and 88.1% had an asymptomatic recurrence. The disease-free interval was not related to the recurrence site. In univariate analysis, primary treatment, recurrence site, and diagnostic method were significant factors for survival outcomes. In contrast, multivariate analysis indicated that only primary treatment was a significant factor. In patients with local recurrence, multivariate analysis demonstrated that radiation as salvage therapy was an independent predictive factor for overall survival after recurrence.

conclusionsIn this retrospective study, routine imaging analysis and serum biomarker measurement did not contribute to patient prognosis after recurrence. In contrast, vaginal vault cytology can improve survival after recurrence in some patients. Tailored surveillance methods based on individual disease conditions and treatment modalities can improve post-recurrent survival outcomes.

Indexed as

Uterine Cervical NeoplasmsCytodiagnosisFemaleHumansNeoplasm Recurrence, LocalPrognosisRetrospective StudiesVaginaCervical cancerLocal recurrencePapanicolaou smear testSurveillance

Identifiers

PMID37081439
PMCPMC10116747
OpenAlexW4366525422

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.